Replies to post #1743 on CardioVascular BioTherapeutics (fka CVBT)

[johnnyblades2001]

Patent Edition FAKE NEWS AGAIN: Examples inside

Let me point out several examples of development stage Biotech companies with No Revenues and No Approved products that were afforded valuations in the BILLIONS

Avexis was a clinical stage biotech company that was purchased Novartis for 8.7 Billion. One patent, one drug in development.


Heres one where Pfizer paid almost a billion in upfront and milestone payments for Therachon using a form of FGF. No revenues, no approved products.

https://investors.pfizer.com/investor-news/press-release-details/2019/Pfizer-Acquires-Clinical-Stage-Biotech-Therachon/default.aspx

Here is an article directly dispute the Patent fake news put forth by some. Explaining why valuing Biotechs is different than other companies.

https://www.toptal.com/finance/valuation/biotech-valuation


Gilead bought Kite Pharma - no revenue, no products, paid $12 billion and Kite Pharma was $600 million in the hole.

There are many, many, many other examples. A quick Google search should surface a number of them.

[heartdr]

I have taken the liberty of reposting Slalom's excellent post on the importance of patents. The quote from the acknowledged experts at building a patent estate, Novo Nordisk says it all. It's why they are a 100 year old company valued at $120bn

"A great article from U.N. agency, World International Patent Organisation - WIPO.

Patents at the Core: the Biotech Business

"“Life sciences and biotechnology are widely regarded as one of the most promising frontier technologies for the coming decades."

In the Shoes of Investors
“Anyone, I would imagine, who has tried to create a biotech company knows just how important patents are. You learn this when you’re studying, and again at your first job, and if you haven’t done so before, you realize it the first time you meet potential investors.” (Mads Øvlisen, Chairman of the Board of Directors, Novo Nordisk)."